Synonym
KCN1; KCN-1; KCN 1.
IUPAC/Chemical Name
3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide
InChi Key
IPZJNJPAVPZHJM-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H27NO5S/c1-26(2)15-14-20-16-19(10-12-23(20)32-26)18-27(21-8-6-5-7-9-21)33(28,29)22-11-13-24(30-3)25(17-22)31-4/h5-17H,18H2,1-4H3
SMILES Code
O=S(C1=CC=C(OC)C(OC)=C1)(N(CC2=CC(C=CC(C)(C)O3)=C3C=C2)C4=CC=CC=C4)=O
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
The following data was from PLoS One . 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep 13.
Figure 1. In vitro anticancer activities of KCN1 against pancreatic cancer cells. (B) Cell growth inhibitory activity of KCN1 in human pancreatic cancer cells. Cells were exposed to various concentrations of KCN1 for 72 h, followed by an MTT assay. ( Source: PLoS One . 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep 13. )
Figure 1. In vitro anticancer activities of KCN1 against pancreatic cancer cells. (B) Cell growth inhibitory activity of KCN1 in human pancreatic cancer cells. Cells were exposed to various concentrations of KCN1 for 72 h, followed by an MTT assay. (
)
Preparing Stock Solutions
The following data is based on the
product
molecular weight
465.56
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Wang W, Ao L, Rayburn ER, Xu H, Zhang X, Zhang X, Nag SA, Wu X, Wang MH, Wang H, Van Meir EG, Zhang R. KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One. 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep 13. PubMed PMID: 23028659; PubMed Central PMCID: PMC3441526.
2: Yin S, Kaluz S, Devi NS, Jabbar AA, de Noronha RG, Mun J, Zhang Z, Boreddy PR, Wang W, Wang Z, Abbruscato T, Chen Z, Olson JJ, Zhang R, Goodman MM, Nicolaou KC, Van Meir EG. Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP. Clin Cancer Res. 2012 Nov 21. [Epub ahead of print] PubMed PMID: 22923450; PubMed Central PMCID: PMC3518680.
